

Anti-ERBB2/HER2/CD340 Antibody (Margetuximab)

Introduction

Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody with an optimized Fc domain and an EC50 of 39.33 ng/mL. Margetuximab can be used in metastatic HER2-positive breast cancer research.

Product parameters

Alternative Names	MARGENZA, MGAH22, 4D5
Target Accession	P04626
Target	ERBB2 / HER2 / CD340
CAS number	1350624-75-7
Molecular Weight	146.1 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80 °C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com